Safety reports and product-quality concerns

Safety information and causation

An adverse event is an unwanted medical occurrence reported in connection with use of a product. Reporting a suspected event does not by itself prove that the product caused it. Equally, uncertainty about causation is not a reason to ignore a concern.

WHO’s pharmacovigilance programme addresses the safer use of medicines and vaccines and the assessment of benefits and risks throughout the lifecycle. The FDA reporting guidance provides an example of a national system for reporting serious product problems; the appropriate local route depends on the country and product.

A product-quality concern

A quality complaint concerns a possible problem with the product or its presentation. Examples of observations include damaged packaging, an unexpected appearance, an inconsistent label or a problem with a delivery component. A report should describe the observation rather than assert an unverified technical cause.

A quality concern and an adverse event can occur together. Keeping both descriptions visible helps the receiving organisation understand why the report may need more than one type of assessment.

Suspected falsified or misrepresented products

WHO distinguishes substandard and falsified medical products and explains the public-health risks associated with them. A suspicion should be referred through the appropriate authority and verified company contact channels; appearance alone may not resolve authenticity.

A copied logo, photograph or brand name is not proof that a product came from the company named on it. If a product is claimed to come from a facility that is still under development, preserve the seller information and seek clarification rather than assuming the claim is genuine.

Information that makes a report useful

• Product name, strength, dosage form and manufacturer as printed.
• Batch or lot number and expiry date, if available.
• Country and where the product was obtained.
• A plain description of what happened or what looked wrong.
• Relevant dates and whether medical attention was needed.
• A contact method for follow-up, using the appropriate reporting route.

Keep original packaging and relevant transaction records if it is safe to do so. Do not send physical samples without instructions from the receiving organisation, and do not publish patient details in an open forum.

Privacy and urgency

Use only the personal information needed for the reporting purpose and the receiving route. A public website form or general business enquiry is not the place to upload complete medical records or identity documents.

If there is an urgent medical problem, seek care from a qualified healthcare professional or local emergency service. Reporting a suspected product problem does not replace treatment, and a company mailbox should not be assumed to operate as an emergency channel.

Contacting Luang Pharma

The Boten facility is under construction and no Luang Pharma portfolio medicine is presented as commercially supplied. A concern involving a product represented as Luang Pharma, suspected company impersonation or a relevant project enquiry may be raised using the safety reporting page.

That route provides the company’s current contact information and scope. It should not be interpreted as a claim that an operational marketed-product pharmacovigilance system, a particular response time or a regulatory case-processing service has been established.

Triage the report without forcing one category

A report may contain more than one issue. A suspected adverse event can occur alongside a damaged container, suspected temperature excursion or authenticity concern. Record the facts under each relevant heading instead of forcing the report into a single category before it has been assessed.

An initial report does not need to be perfect. Capture the reporter contact route, product and batch information where available, what happened, when and where it occurred, and whether urgent medical attention is needed. Missing details can be followed up later through an appropriate process.

A general mailbox is not a pharmacovigilance system

An email address can provide a route for an initial message, but it does not by itself establish continuous monitoring, case processing, medical assessment, regulatory reporting timelines or a validated safety database. Those operating responsibilities need named ownership, procedures and appropriate systems.

The Luang Pharma website therefore describes the published address as a general company contact and also points reporters to competent national authorities. It does not display a false “report received” confirmation when no verified submission service exists.